The case for a biologically based classification of prostate cancer.
It is axiomatic that integrated multidisciplinary therapy based on the understanding of malignancy is required for the cure of adult cancer. In successful examples, agents (chemotherapy, biologics) and other modalities (radiation, surgery) are applied on the basis of clinical biology. The understanding of the clinical biology and the development of a classification based on relevant clinical and biological features is central to therapy development.
Logothetis
Christopher J
CJ
Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Center, Houston, TX 77030, USA.
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003043:Cocarcinogenesis; D003131:Combined Modality Therapy; D018450:Disease Progression; D020022:Genetic Predisposition to Disease / Q000145:classification* / Q000235:genetics*; D006801:Humans; D008297:Male; D008967:Molecular Biology / Q000379:methods*; D009154:Mutation / Q000235:genetics; D010348:Patient Care Team; D018579:Patient Selection; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000145:classification* / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy
D000726:Androgen Antagonists; D000970:Antineoplastic Agents